Logo

    asrs

    Explore " asrs" with insightful episodes like "Unleashing the Power of Warehouse Execution Systems with Art Eldred", "EP 138: AutoGuide Mobile ASRS", "Al Alaimo - FX Portfolio Manager at Arizona State Retirement System", "EP 103: Swisslog at MODEX" and "From West Point to ONL’s C-Suite - David Esposito" from podcasts like ""eCom Logistics Podcast", "The New Warehouse Podcast", "The HPScast", "The New Warehouse Podcast" and "OIS Podcast | Ophthalmology's leading Podcast"" and more!

    Episodes (42)

    Unleashing the Power of Warehouse Execution Systems with Art Eldred

    Unleashing the Power of Warehouse Execution Systems with Art Eldred

    Art Eldred is a seasoned Supply Chain Executive with over 20 years of expertise, specializing in eCommerce fulfillment solutions. He adeptly leads cross-functional teams, including consultants, mechanical, controls, and software engineers. Art's early career with a startup electromechanical software company provided invaluable insights into highly successful software organizations. His management approach emphasizes creativity while delivering robust solutions. His extensive knowledge of material handling technologies, coupled with software integration, leads to innovative, replicable solutions. Art serves as a trusted advisor to numerous supply chain C-level executives, offering insights on best practices, new technologies, and software integration. His designs are constantly recognized for their impact, often featured in industry publications and conferences, delivering speed, efficiency, and simplicity to his clients.

    SHOW SUMMARY

    In this episode of eCom Logistics Podcast, Art Eldred, Vice President and Growth Officer at Vargo, discusses warehouse execution systems (WES). He explains that a WES is a system that executes tasks and flows within a fulfillment operation, managing the workflow and synchronizing and sequencing work tasks. Art emphasizes the importance of decoupling processes and leveraging technology to optimize workflows. He also highlights the need for clear definitions and understanding of WES, as many companies market solutions that are simply dashboarding systems. Art, Dan, and Ninaad discuss the evolution of automation in the industry, including the accessibility of technology and the emergence of robotic solutions. They stress the importance of aligning different departments within an organization and the value of integrating various technologies to achieve efficiency and productivity.

    HIGHLIGHTS

    [00:01:17] Art's background and professional journey in e-commerce fulfillment
    [00:03:11] Art's passion for bringing together software and hardware in logistics
    [00:08:55] Definition of a warehouse execution system (WES)
    [00:15:16] Successful implementation of a WES project
    [00:20:25] The trade-off between expediency and efficiency
    [00:25:06] When to consider implementing a warehouse execution system
    [00:30:01] The evolving role of automation in warehousing
    [00:34:07] Importance of integrating different capabilities and not leaving them in silos
    [00:36:06] Excitement about the accessibility of automation technology
    [00:40:13] The difference between a warehouse execution system (WES) and a warehouse management system (WMS)

    QUOTES

    [00:03:12] "My passion isn't one or the other, it's bringing it all together." - Art Eldred
    [00:04:51] "The warehouse execution system sits below the warehouse management system and it's managing the workflow." - Art Eldred
    [00:14:10] "The warehouse execution system can really unleash the capabilities of both the software element and the hardware and technology world." - Art Eldred

    Find out more about Art Eldred in the link below:
    LinkedIn: https://www.linkedin.com/in/arteldred/

    EP 138: AutoGuide Mobile ASRS

    EP 138: AutoGuide Mobile ASRS

    In this episode host Kevin Lawton talks to the CEO of AutoGuide Mobile Robots, Rob Sullivan. They discuss AutoGuide's business during the pandemic, their new Mobile ASRS, their new MAX-N High Bay and their modular robot platform.

    Utilize our 3PL fulfillment services for all of your logistical needs. Email Kevin directly at kevin@thenewwarehouse.com

    Free floor tape and floor sign samples from Mighty Line! Get yours here.

    Follow us on LinkedIn here for more content.

    Support the show

    From West Point to ONL’s C-Suite - David Esposito

    From West Point to ONL’s C-Suite - David Esposito

    This week’s special guest on the OIS Retina Podcast is David Esposito, CEO of ONL Therapeutics. A West Point graduate who served as a platoon leader in the first Gulf War, Esposito began his career in ophthalmology as a pharmaceutical sales rep for Merck. This led to several executive positions and eventually to building and scaling private companies. His career came full circle when investors recruited him to ONL Therapeutics a year ago. In this episode, host Firas Rahhal, MD, digs into ONL’s portfolio of therapies in development, the latest on the company’s clinical trials, and how as a corporate leader Esposito draws on his military experience.

    OIS Retina Podcast: Interview with Serial Inventor Dr. Mark Humayun

    OIS Retina Podcast: Interview with Serial Inventor Dr. Mark Humayun

    This week marks the official launch of the OIS Retina Podcast with host Firas Rahhal, MD, interviewing world-renowned retina specialist and serial inventor Mark Humayun, MD, PhD, as his first guest. Here are a few impressive facts about Dr. Humayun:
    • He’s the director of the Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics at the University of Southern California and co-director of the USC Roski Eye Institute.
    • He’s a professor of ophthalmology and a biomedical engineer.
    • He received numerous research awards, including the 2005 Innovator of the Year Award.
    • He was featured as one of the Top 10 Inventors by Time magazine in 2013.
    • In 2016 he received the National Medal of Technology and Innovation from President Barack Obama for his innovative work on the Argus retinal prosthesis.
    • He was awarded the 2020 Medal for Innovations in Healthcare Technology by the Institute of Electrical and Electronics Engineers.
    • He’s written over 200 publications and filed over 100 patents.
    • He’s been consistently voted as One of the Top Doctors in the World.
    • He was once a guest on the Howard Stern Show!

    Listen in to hear how Dr. Rahhal compares to the King of All Media.

    Bill Link’s Road to Ophthalmology and VC

    Bill Link’s Road to Ophthalmology and VC

    OIS Israel Co-Chair William J. Link, PhD, of Flying L Partners, shares some business life lessons and the unique sequence of events that led him into ophthalmology and eventually venture capital. Dr. Link also discusses the impact of COVID-19 on his portfolio companies and predictions on when and how we as an industry will come out of this. Don’t miss this highly informative and entertaining discussion between Ehsan Sadri, MD, and the man he calls “the Phil Jackson of ophthalmology.”

    Leadership - How to Measure & Motivate in a Startup Environment

    Leadership - How to Measure & Motivate in a Startup Environment

    For this episode of the OIS Podcast, we are sharing a panel discussion on Leadership which took place during the last OIS@AAO meeting in San Francisco.

    The focus of the conversation was on “How to Measure and Motivate in a Startup Environment” and featured some valuable insights from Adrienne Graves, Bernie Haffey, Ron Kurtz, Kirk Nielsen, and Andy Corley.

    Participants:
    Adrienne Graves, PhD, Independent Board Member - Nicox, IVERIC, Oxurion, Akorn, Greenbrook TMS, Surface Pharma
    Bernie Haffey, President - Haffey & Co.
    Ron Kurtz, MD, President & CEO - RxSight
    Kirk Nielsen, Managing Partner - Vensana Capital

    Moderated By:
    Andy Corley, Principal - Yelroc Consulting

    Join us this year at the 12th Annual OIS – November 12, 2020 » Las Vegas, NV
    https://ois.net/12th-annual-ois

    Bobak Azamian CEO of Tarsus Addresses Unmet Needs in Blepharitis

    Bobak Azamian CEO of Tarsus Addresses Unmet Needs in Blepharitis

    In January of 2020, Tarsus raised $60 million Series B financing round to initiate Phase 2b/3 trial in the U.S. of their lead product TP-03 for Demodex blepharitis. In this episode, Bobby Azamian shares his background and path to ophthalmology, details on their clinical trials and practical advice for entrepreneurs.

    Interviewer:
    Ehsan Sadri, MD
    Managing Partner
    Visionary MD Eye Laser institute

    Guest:
    Bobak Azamian, MD, PhD
    CEO
    Tarsus

    Are you interested in being an OIS Podcast guest or interested in presenting at one of our upcoming showcases?

    Visit OIS.net for more info – https://ois.net/get-involved

    Robert Dempsey New CEO of TearClear

    Robert Dempsey New CEO of TearClear

    This week’s OIS Podcast has breaking news on Robert Dempsey, the new CEO of TearClear, which came at the close of a Series B financing round. Listen to how he plans to take TearClear through the next stages of development.

    Interviewer:
    Ehsan Sadri, MD
    Managing Partner
    Visionary MD Eye Laser institute

    Interviewee:
    Robert Dempsey
    CEO
    TearClear

    If you are interested in being an OIS Podcast Guest or interested in being a Presenter at one of our upcoming showcases – Visit https://ois.net/get-involved

    Collaborative Care in Cataracts & Ocular Surface Disease

    Collaborative Care in Cataracts & Ocular Surface Disease

    In this special episode of the OIS podcast, we have a discussion that took place during the recent OIS@SECO in Atlanta. Summit Co-Chairman, Paul Karpecki, OD, FFAO, set the stage with some staggering figures which led to an insightful conversation between two ODs and two MDs about Collaborative Care models and the benefits to both patients and practices.

    Participants:
    Thomas Chester, OD, Clinical Director - Cleveland Eye Clinic
    Elise Kramer, OD, FAAO - Miami Contact Lens Institute
    William Trattler, MD, Director of Cornea - Center For Excellence In Eyecare
    William Wiley, MD - Cleveland Eye Clinic

    Moderated By:
    Paul Karpecki, OD, FAAO, Associate Professor - UPike College of Optometry/Kentucky Eye Institute

    More on OIS@SECO 2020:
    https://ois.net/ois-seco-2020

    J&J Vision’s Newly Appointed Worldwide President of Surgical, Mr. Warren Foust Meets with OIS Podcast

    J&J Vision’s Newly Appointed Worldwide President of Surgical, Mr. Warren Foust Meets with OIS Podcast

    This past week OIS Podcast host, Dr. Ehsan Sadri had the opportunity to chat with J&J Vision’s newly appointed Worldwide President of Surgical, Mr. Warren Foust.  In this episode Warren describes his background leading up to this new position. He also shares his “vision” for the organization moving forward, how they plan to enhance the customer experience and challenges to addressing unmet vision needs.

    REGISTER for our next ophthalmology conference today – OIS.net

    Part II: OIS Co-chair Emmett Cunningham, Jr. Delivers Annual Overview on the State of Ophthalmology

    Part II: OIS Co-chair Emmett Cunningham, Jr. Delivers Annual Overview on the State of Ophthalmology
    In part one of a two-part podcast, OIS co-chair and Clarus Funds managing director Emmett Cunningham, Jr., MD, PhD, MPH, delivers a 360-degree review of ophthalmology’s more promising pipelines. To download a copy of an extended version of the Year in Review report delivered at OIS@AAO click here.

    Dry Eye Diaries: Hear Tales and Hopes from Leaders of Shire, Johnson & Johnson, and TearSolutions

    Dry Eye Diaries: Hear Tales and Hopes from Leaders of Shire, Johnson & Johnson, and TearSolutions
    In interviews at OIS@AAO, we talk with Robert Dempsey, global head of Shire’s ophthalmic business, about the international launch of Xiidra. Joseph Boorady, CEO and president of TearScience, lays out the company’s plans since being acquired by Johnson & Johnson Vision. Finally, Tom Gadek, president and CEO of TearSolutions, explains how he’s hoping to score another winning dry eye treatment with a start-up.

    CEO Brent Saunders Lays out Allergan’s Plans for Ophthalmology, Restasis, and Innovation

    CEO Brent Saunders Lays out Allergan’s Plans for Ophthalmology, Restasis, and Innovation
    Brent Saunders, president, CEO, and chairman of global leader Allergan, sits down at OIS@AAO to discuss what impact the pending loss of the Restasis patent could have on the company. He also rejects talk of Allergan breaking off its ophthalmology business, saying the company is in the sector to stay.

    Donnenfeld, MD, Talks Blue Sea PE Deal, OD/MD Collaboration, and Why OCLI Got CheckedUp

    Donnenfeld, MD, Talks Blue Sea PE Deal, OD/MD Collaboration, and Why OCLI Got CheckedUp
    Eric Donnenfeld, MD, founding partner of Ophthalmology Consultants of Long Island, explains how his practice will use a capital infusion from growth equity firm Blue Sea Capital. Dr. Donnenfeld also opines on the growing cooperation - and competition - between ophthalmologists and optometrists. Plus, he explains how he uses CheckedUp to engage his patients.

    OIS Co-Chair Emmett Cunningham Walks through the Upcoming OIS@AAO Agenda, Reveals New Ways to Engage

    OIS Co-Chair Emmett Cunningham Walks through the Upcoming OIS@AAO Agenda, Reveals New Ways to Engage
    OIS co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, talks about OIS’ evolution over nearly a decade of meetings. The addition of Breakfast Breakout Sessions and Master Classes has opened opportunities for speakers and attendees. Dr. Cunningham, a partner at Clarus, also walks us through the agenda of next week’s OIS@AAO in New Orleans. This year’s agenda includes several new topics and formats as well as the return of a familiar face on stage.

    Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors

    Aerie CEO Anido Talks War Rooms, FDA, Rhopressa, Roclatan, and Getting Along with the Neighbors
    Aerie Pharmaceuticals scored an impressive win at the recent FDA advisory panel, getting a thumbs up for the approval of Rhopressa. In this interview, CEO Vince Anido explains how Aerie plans to move forward with its lead glaucoma product. He also tells how its new drug-delivery technology will fit into its plans. In addition, we get an update on the late-stage trials of Roclatan.

    Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease

    Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease
    Ophthalmology companies have had a difficult time targeting AMD lately. Newcomer Gemini Therapeutics is bringing a “multimodal approach” to identify new targets in the complement system, with an eye toward developing specific treatments for patients with connected genetic codes. CEO, president, and co-founder James McLaughlin explains how Gemini hopes to advance the war against these dreadful diseases.
    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io